Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 14, 2015
- Accepted in final form October 1, 2015
- First Published December 10, 2015.
Author Disclosures
- Catharina C. Gross, PhD*,
- Andreas Schulte-Mecklenbeck*,
- Svenja Klinsing,
- Anita Posevitz-Fejfár, PhD,
- Heinz Wiendl, MD and
- Luisa Klotz, MD
- Catharina C. Gross, PhD*,
NONE
NONE
I received speaker honoraria and travel expenses for attending meetings from Genzyme, Novartis Pharma GmbH, and Bayer Health Care.
Frontiers in Immunology, Review Editor, Since 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Research Foundation (DFG), GR3946/2-1, 01/2013-12/2015
Innovative Medical Science Grant (IMF-grant) of the medical faculty of the University of M?nster, KL111421, 07/2014-06/2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andreas Schulte-Mecklenbeck*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Svenja Klinsing,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anita Posevitz-Fejfár, PhD,
NONE
NONE
Genzyme, honoraria and travel costs
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD and
(1) Bayer Healthcare, (2) Biogen Idec, (3) Sanofi- Genzyme, (4) Merck Serono, (5) Novartis, (6) Roche, (7) Tev
NONE
(1) Bayer Vital GmbH, (2) Bayer Schering AG, (3) Biogen, (4) CSL Behring, (5) EMD Serono, (6) Fresenius Medical Care, (7) Sanofi - Genzyme, (8) Merck Serono, (9) Omniamed, (10) Novartis, (11) Teva
(1) Journal of Clinical Practice, Editorial Board member, since 2006 (2) Journal of Neuroinflammation, Editorial Board member, since 2007 (3) PLOS ONE, Editorial board member, since 2013
NONE
NONE
NONE
(1) Biogen Idec, (2) Merck Serono, (3) Novartis, (4) Omniamed, (5) Roche (6) Sanofi-Genzyme.
NONE
NONE
NONE
(1) Bayer Healthcare, (2) Bayer Vital, (3) Biogen Idec, (4) Merck Serono, (5) Novartis, (6) Sanofi ? Genzyme, (7) Sanofi US (8) TEVA Pharma
(1) German Ministry for Education and Research (BMBF), BD120300, Principal Investigator, 2012-2015 (2) German Ministry for Education and Research (BMBF), BD604262, Principal Investigator, 2013-2016 (3) Deutsche Forschungsgesellschaft (DFG), WI 1722/12-1, Principal Investigator, 2012-2015 (4) Deutsche Forschungsgesellschaft (DFG), WI 1722/13-1, Principal Investigator, 2012-2015(5) European Union, BD604219, 2013-2015(6) Deutsche Forschungsgesellschaft (DFG), SFB 1009 TP A3, Principal Investigator, 2012-2015(6) Deutsche Forschungsgesellschaft (DFG), SFB 128 TP A9, Principal Investigator, 2012-2015 (7) Deutsche Forschungsgesellschaft (DFG), SFB 128 TP B1, Principal Investigator, 2012-2015 (8) Deutsche Forschungsgesellschaft (DFG), SFB 128 TP Z2, Principal Investigator, 2012-2015 Else Kr?ner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, Merck Serono, Novartis, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, RE Children?s Foundation.(5) Novartis(6) Sanofi Aventis NovoNordisk)
NONE
(1) Else Kr?ner Fresenius Foundation, (2) Fresenius Foundation, (3) Hertie Foundation, (4) RE Children?s Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa Klotz, MD
(1) Genzyme
NONE
(1) Novartis, speaker honoraria and travel support (2) Merck Serono, speaker honoraria and travel support (3) CSL Behring, speaker honoraria and travel support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis, (2) Biogen
(1) CRC TR128 ?Initiating/Effector versus Regulatory Mechanisms in Multiple Sclerosis ? Progress towards Tackling the Disease?, Project A8
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Correspondence to Dr. Klotz: Luisa.klotz{at}ukmuenster.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.